Last updated: 11/07/2018 17:00:48
A study to investigate the effectiveness of fluticasone propionate (FP) 200 mg/day versus beclomethasone dipropionate (BDP) 400 mg/day delivered via the Babyhaler™ spacer device in patients with a history of wheeze aged 2 to 18 months.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A study to investigate the effectiveness of fluticasone propionate (FP) 200 mg/day versus beclomethasone dipropionate (BDP) 400 mg/day delivered via the Babyhaler™ spacer device in patients with a history of wheeze aged 2 to 18 months.
Trial description: A study to investigate the effectiveness of fluticasone propionate (FP) 200 mg/day versus beclomethasone dipropionate (BDP) 400 mg/day delivered via the Babyhaler™ spacer device in patients with a history of wheeze aged 2 to 18 months.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Kraemer R, Graf Bigler U, Casaulta Aebischer C. Comparative efficacy of fluticasone propionate 200mcg daily and beclomethasone dipropionate 400mcg daily in combination with salbutamol, delivered via the BabyhalerTM spacer device in wheezy infants. Eur Respir J 1996; 9 (suppl 23): 114s.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1995-15-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website